Cyltezo Becomes First FDA-Approved Interchangeable Humira Biosimilar
XTalks
OCTOBER 22, 2021
Boehringer Ingelheim’s Cyltezo has become the second interchangeable biosimilar approved by the FDA, and the first approved interchangeable monoclonal antibody. In July 2021, the agency approved the first interchangeable biosimilar product, Semglee (insulin glargine-yfgn) for the treatment of diabetes.
Let's personalize your content